BML Capital Management »

Janux Therapeutics shares owned by BML Capital Management

Quarter-by-quarter ownership of Janux Therapeutics (JANX) shares owned by BML Capital Management from 13F filings

Historical chart of BML Capital Management investment in Janux Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Janux Therapeutics held by BML Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Janux Therapeutics by BML Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.2M 155k 13.90

More positions owned by BML Capital Management

Aclaris Therapeutics (ACRS)
Atea Pharmaceuticals (AVIR)
Oramed Pharmaceuticals Com New (ORMP)
Tillys Cl A (TLYS)
Outset Med Com New (OM)
Pmv Pharmaceuticals (PMVP)
CarMax (KMX)
Kezar Life Sciences Com New (KZR)
Instil Bio Com New (TIL)
Target Corporation (TGT)
Kraft Heinz (KHC)
Janux Therapeutics (JANX)
Pliant Therapeutics (PLRX)
Connect Biopharma Hldgs SHS (CNTB)
Imagenebio (IMA)

View all positions for BML Capital Management

Top funds holding Janux Therapeutics

RA Capital Management
BlackRock
State Street Corporation
FMR
Vanguard Group
Prosight Management
OrbiMed Advisors
Vanguard Capital Management
TCG Crossover Management
Wellington Management Company
Alyeska Investment Group
Vanguard Portfolio Management
Citadel Advisors
Geode Capital Management
Goldman Sachs Group

View all funds holding Janux Therapeutics